Skip to Content

AbbVie Inc ABBV

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Stewardship

PREMIUM

President Trump’s Updated Healthcare Policy Targets Drug Costs, but Implementation Looks Tough

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

President Donald Trump updated the administration’s healthcare policy to include new drug benefit cards for seniors and executive orders supporting insurance protection for pre-existing conditions and increased clarity around medical billing. We don’t expect any major changes to our fair value estimates or moat ratings based on the announcements, but the updates slightly increase uncertainty within the drug industry. The updates add to executive orders issued over the past two months, including international drug importation, Medicare drug price setting based on international prices, elimination of drug rebates in the supply channel, and the minor expansion of 340b drug discounts (targeting low-income patients) for certain drugs (see July 27 note for more details).

Read Full Analysis

Company Profile

Business Description

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013. The recent announced acquisition of Allergan will add several new drugs in aesthetics and women's health.

Contact
1 North Waukegan Road
North Chicago, IL, 60064-6400
T +1 847 932-7900
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Jun 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type High Yield
Employees 47,000

Related